Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin

ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation

(2015) Gabriele D’Uva et al.   NATURE CELL BIOLOGY

RETRACTED: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase

(2014) Peter Littlefield et al.   CHEMISTRY & BIOLOGY

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

(2013) A. P. Garner et al.   CANCER RESEARCH

HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation

(2012) D. B. Vaught et al.   CANCER RESEARCH

Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study

(2012) Petra dos Santos et al.   Diagnostic Pathology

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

(2012) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS

A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines

(2011) Edith Blackburn et al.   BREAST CANCER RESEARCH AND TREATMENT

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Important role of integrins in the cancer biology

(2010) R. Rathinam et al.   CANCER AND METASTASIS REVIEWS

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

(2010) B. Schoeberl et al.   CANCER RESEARCH

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

(2010) M. R. Campbell et al.   CLINICAL CANCER RESEARCH

Cross-talk between the insulin-like growth factor (IGF) axis and membrane integrins to regulate cell physiology

(2010) James Beattie et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Integrins as therapeutic targets: lessons and opportunities

(2010) Dermot Cox et al.   NATURE REVIEWS DRUG DISCOVERY

 1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression

(2010) L. Huck et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver

(2010) D. N. Amin et al.   Science Translational Medicine

Signal co-operation between integrins and other receptor systems

(2009) Charles H. Streuli et al.   BIOCHEMICAL JOURNAL

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

(2009) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury

(2009) Kevin Bersell et al.   CELL

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

(2009) N. Jura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

(2008) S. T. Lee-Hoeflich et al.   CANCER RESEARCH

The epidermal growth factor receptor family: Biology driving targeted therapeutics

(2008) M. J. Wieduwilt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES